Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.
Latest Ratings for PRAX
DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Aug 2021B of A SecuritiesInitiates Coverage OnBuy Apr 2021William BlairInitiates Coverage OnOutperform